Hemab Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire•11/11/2026•07:00 ET
0
Key Highlights
- ➤Hemab management to participate in Jefferies Global Healthcare Conference on November 17, 2026
- ➤Hemab management to participate in Evercore Healthcare Conference on December 1, 2026
- ➤Sutacimig (HMB-001) is in clinical development for Glanzmann thrombasthenia and Factor VII deficiency
- ➤HMB-002 is in clinical development for prophylactic treatment of Von Willebrand Disease
- ➤HMB-003 is in clinical development for heavy menstrual bleeding
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that members of the Hemab Therapeutics management team will participate in the following upcoming investor conferences and host investor meetings.
2026 Jefferies Global Healthcare Conference Fireside Chat: Tuesday, November 17, 2026, at 5:00 PM GMT Location: London, United Kingdom
Get started
Create a free account to read the full story.